Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Breast Cancer: Results from a Multicenter Retrospective Study

References

• GhonchehM, PournamdarZ, SalehiniyaH. Incidence and mortality and epidemiology of breast cancer in the world. Asian Pac J Cancer Prev. 2016;17(S3):43–46. doi:10.7314/APJCP.2016.17.S3.43
   PubMedGoogle Scholar
• BrayF, FerlayJ, SoerjomataramI, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• National Institute for Cancer Prevention and Research. Globocan 2018: India Factsheet. Available from:http://cancerindia.org.in/globocan-2018-india-factsheet/. Accessed 421, 2020.
   Google Scholar
• CrownJ, O’LearyM, OoiWS. Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist. 2004;9Suppl 2(S2):24–32. doi:10.1634/theoncologist.9-suppl_2-24
   Web of Science ®Google Scholar
• Taxotere® Prescribing Information. sanofi-aventis U.S. LLC, NJ 08807. Revised5, 2010.
   Google Scholar
• AmatS, BougnouxP, Penault-LlorcaF, et al. Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. Br J Cancer. 2003;88(9):1339–1345. doi:10.1038/sj.bjc.660091612778058
   PubMed Web of Science ®Google Scholar
• von MinckwitzG, UntchM, BlohmerJU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796–1804. doi:10.1200/JCO.2011.38.859522508812
   PubMed Web of Science ®Google Scholar
• WeiszhárZ, CzúczJ, RévészC, et al. Complement activation by polyethoxylated pharmaceutical surfactants: cremophor-EL, Tween-80 and Tween-20. Eur J Pharm Sci. 2012;45(4):492–498. doi:10.1016/j.ejps.2011.09.01621963457
   PubMed Web of Science ®Google Scholar
• PritchettW, KinsleyK. Benefits and risks of fosaprepitant in patients receiving emetogenic regimens. Clin J Oncol Nurs. 2016;20(5):555–556. doi:10.1188/16.CJON.555-55627668376
   PubMed Web of Science ®Google Scholar
• FumoleauP, Tubiana-HulinM, SoulieP, et al. A dose finding and pharmacokinetic (PK) Phase I study of a new formulation of docetaxel (D) in advanced solid tumors. [abstract]. Ann Oncol. 1998;9(Suppl. 2):101.9541690
   PubMed Web of Science ®Google Scholar
• Ten TijeAJ, VerweijJ, LoosWJ, SparreboomA. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet. 2003;42(7):665–685. doi:10.2165/00003088-200342070-0000512844327
   PubMed Web of Science ®Google Scholar
• CoorsEA, SeyboldH, MerkHF, MahlerV. Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. Ann Allergy Asthma Immunol. 2005;95(6):593–599. doi:10.1016/S1081-1206(10)61024-116400901
   PubMed Web of Science ®Google Scholar
• SchwartzbergLS, NavariRM. Safety of polysorbate 80 in the oncology setting. Adv Ther. 2018;35(6):754–767. doi:10.1007/s12325-018-0707-z29796927
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication (2014, 620). FDA warns that cancer drug docetaxel may cause symptoms of alcohol intoxication after treatment. Available From:https://www.fda.gov/Drugs/DrugSafety/ucm401752.htm. Accessed 421, 2020.
   Google Scholar
• MirzaA, MithalN. Alcohol intoxication with the new formulation of docetaxel. Clin Oncol (R Coll Radiol). 2011;23(8):560–561. doi:10.1016/j.clon.2011.04.01021571513
   PubMed Web of Science ®Google Scholar
• PiccartMJ, KlijnJ, ParidaensR, et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European organization for research and treatment of cancer investigational drug branch for breast cancer. J Clin Oncol. 1997;15(9):3149–3155. doi:10.1200/JCO.1997.15.9.31499294478
   PubMed Web of Science ®Google Scholar
• JungJW, ChoiYH, ParkCM, et al. Outcomes of corticosteroid prophylaxis for hypersensitivity reactions to low osmolar contrast media in high-risk patients. Ann Allergy Asthma Immunol. 2016;117(3):304–309.e301. doi:10.1016/j.anai.2016.07.01027613465
   PubMed Web of Science ®Google Scholar
• AlkenS, KellyCM. Benefit risk assessment and update on the use of docetaxel in the management of breast cancer. Cancer Manag Res. 2013;5:357–365. doi:10.2147/CMAR.S4932124143122
   PubMedGoogle Scholar
• WeissRB, DonehowerRC, WiernikPH, et al. Hypersensitivity reactions from taxol. J Clin Oncol. 1990;8(7):1263–1268. doi:10.1200/JCO.1990.8.7.12631972736
   PubMed Web of Science ®Google Scholar
• AhmadA, SheikhS, TaranR, et al. Therapeutic efficacy of a novel nanosomal docetaxel lipid suspension compared with taxotere in locally advanced or metastatic breast cancer patients. Clin Breast Cancer. 2014;14(3):177–181. doi:10.1016/j.clbc.2013.09.01124287370
   PubMed Web of Science ®Google Scholar
• AshrafM, SajjadR, KhanM, et al. 156P Efficacy and safety of a novel nanosomal docetaxel lipid suspension (NDLS) as an anti cancer agent-a retrospective study. Ann Oncol. 2016;27(suppl_9). doi:10.1093/annonc/mdw579.008.
   Google Scholar
• MuraliA, GuptaS, PendharkarD. Efficacy and tolerability of nanoparticle docetaxel lipid suspension. J Clin Oncol. 2018;36(15_suppl):e14542–e14542. doi:10.1200/JCO.2018.36.15_suppl.e14542
   Web of Science ®Google Scholar
• EisenhauerEA, TherasseP, BogaertsJ, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.02619097774
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Available from:https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed 421, 2020.
   Google Scholar
• National Comprehensive Cancer Network (NCCN). Breast Cancer Guidelines 2019.
   Google Scholar
• CardosoF, SenkusE, CostaA, et al. 4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4)†. Ann Oncol. 2018;29(8):1634–1657. doi:10.1093/annonc/mdy19230032243
   PubMed Web of Science ®Google Scholar
• AhmadA, SheikhS, AliSM, et al. Development of aqueous based formulation of docetaxel: safety and pharmacokinetics in patients with advanced solid tumors. J Nanomed Nanotechnol. 2015;6(3):1.
   Google Scholar
• NaikR, KhanMA. Doceaqualip in a patient with prostate cancer who had an allergic reaction to conventional docetaxel: a case report. Mol Clin Oncol. 2017;6(3):341–343. doi:10.3892/mco.2017.114728451410
   PubMed Web of Science ®Google Scholar
• PrasannaR, BungerD, KhanMA. Efficacy and safety of DoceAqualip in a patient with locally advanced cervical cancer: a case report. Mol Clin Oncol. 2018;8(2):296–299. doi:10.3892/mco.2017.151929435291
   PubMed Web of Science ®Google Scholar
• VyasV, JoshiN, KhanM. Novel docetaxel formulation (NDLS) in low cardiac reserve ovarian cancer. Open Access J Cancer Oncol. 2018;2(2):000122.
   Google Scholar
• GuptaS, PawarSS, BungerD. Successful downstaging of locally recurrent penile squamous cell carcinoma with neoadjuvant nanosomal docetaxel lipid suspension (NDLS) based regimen followed by curative surgery. BMJ Case Rep. 2017;2017.
   Google Scholar
• RajappaS, JoshiA, DovalDC, et al. Novel formulations of docetaxel, paclitaxel and doxorubicin in the management of metastatic breast cancer. Oncol Lett. 2018;16(3):3757–3769. doi:10.3892/ol.2018.905730127986
   PubMed Web of Science ®Google Scholar
• SpringL, GreenupR, ReynoldsK, SmithBL, MoyB, BardiaA. Pathological complete response after neoadjuvant chemotherapy predicts improved survival in all major subtypes of breast cancer: systematic review and meta-analyses of over 18,000 patients. Presented at the 2016 AACR Ann Meeting. 2016 Abstract 1439.
   Google Scholar
• LiS, WeiW, JiangY, et al. Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer. Drug Des Devel Ther. 2018;12:3085–3093. doi:10.2147/DDDT.S171534
   PubMed Web of Science ®Google Scholar
• ZuradelliM, GulloG, WalsheJ, et al. 446 docetaxel, carboplatin and trastuzumab (TCH) as Neoadjuvant (neoadj) therapy in patients (pts) with HER2-positive (HER2+) Operable Breast Cancer (BrCa). Eur J Cancer. 2012;48:S177. doi:10.1016/S0959-8049(12)70511-7
   Web of Science ®Google Scholar
• TiwariA, GogiaA, DeoS, et al. Retrospective study of efficacy and safety of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive locally advanced and oligometastatic breast cancer: an Indian experience. Indian J Cancer. 2017;54(1):343–346. doi:10.4103/ijc.IJC_152_1729199719
   PubMed Web of Science ®Google Scholar
• KolbergH-C, Akpolat-BasciL, StephanouM, HannigC, LiedtkeC. Neoadjuvant chemotherapy with docetaxel, carboplatin, and weekly trastuzumab (TCH) activity in HER2-positive early breast cancer: results after a median follow-up of 4.5 years. J Clin Oncol. 2015;33(28_suppl):140. doi:10.1200/jco.2015.33.28_suppl.140
   Web of Science ®Google Scholar
• MartinM. Docetaxel, doxorubicin and cyclophosphamide (the TAC regimen): an effective adjuvant treatment for operable breast cancer. Womens Health. 2006;2(4):527–537. doi:10.2217/17455057.2.4.527
   Google Scholar
• JonesSE, SavinMA, HolmesFA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006;24(34):5381–5387. doi:10.1200/JCO.2006.06.539117135639
   PubMed Web of Science ®Google Scholar
• JonesS, HolmesFA, O’ShaughnessyJ, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of us oncology research trial 9735. J Clin Oncol. 2009;27(8):1177–1183. doi:10.1200/JCO.2008.18.402819204201
   PubMed Web of Science ®Google Scholar
• MartinM, PienkowskiT, MackeyJ, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352(22):2302–2313. doi:10.1056/NEJMoa04368115930421
   PubMed Web of Science ®Google Scholar
• JonesSE, ColleaR, PaulD, et al. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, Phase 2 study. Lancet Oncol. 2013;14(11):1121–1128. doi:10.1016/S1470-2045(13)70384-X24007746
   PubMed Web of Science ®Google Scholar
• Lyseng-WilliamsonKA, FentonC. Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(17):2513–2531. doi:10.2165/00003495-200565170-0000716296875
   PubMed Web of Science ®Google Scholar
• NabholtzJM, SennHJ, BezwodaWR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol. 1999;17(5):1413–1424. doi:10.1200/JCO.1999.17.5.141310334526
   PubMed Web of Science ®Google Scholar
• ChanS. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy. Oncology (Williston Park). 1997;11(8 Suppl 8):19–24.
   Google Scholar
• MavroudisD, AlexopoulosA, MalamosN, et al. Salvage treatment of metastatic breast cancer with docetaxel and carboplatin. A multicenter Phase II trial. Oncology. 2003;64(3):207–212. doi:10.1159/00006930612697959
   PubMed Web of Science ®Google Scholar
• PerezEA, SumanVJ, FitchTR, et al. A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932. Oncology. 2005;69(2):117–121. doi:10.1159/00008781316118507
   PubMed Web of Science ®Google Scholar
• ValeroV, ForbesJ, PegramMD, et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol. 2011;29(2):149–156. doi:10.1200/JCO.2010.28.645021115860
   PubMed Web of Science ®Google Scholar
• RivaA, ReeseD, ToppmeyerD, et al. Results of Two open-label, multicenter phase ii studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. JNCI. 2004;96(10):759–769. doi:10.1093/jnci/djh13315150304
   PubMedGoogle Scholar
• AshrafQM, SajadQR, KhanMA, et al. Efficacy and safety of a novel nanosomal docetaxel lipid suspension as an anticancer agent - a retrospective study. J Cancer Oncol. 2018;2(4):000132.
   Google Scholar